NCT01832116 (Clinical Trial / DMOT4039A / RG7600)

Study Title
89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients (NCT01832116)

Trial Description
The purpose of this multicenter imaging sub study is to evaluate the biodistribution and organ pharmacokinetics of 89Zr-MMOT0530A in patients with unresectable pancreatic or platinum-resistant ovarian cancer. MMOT0530A is a monoclonal antibody that targets an antigen overexpressed in pancreatic and ovarian cancer. Subsequent to imaging with 89Zr-MMOT0530A, patients will be treated with DMOT4039A (also known as RG7600) in the DMO4993g protocol ( identifier NCT01469793) after this study.

DMOT4039A is an antibody-drug conjugate composed of the monoclonal antibody MMOT0530A and the mitotic agent monomethyl auristatin (MMAE). By imaging patients with the monoclonal antibody MMOT0530A before treatment, the correlation between tumor uptake of 89Zr-MMOT0530A and response to DMOT4039A therapy will be assessed.

This trial is sponsored by University Medical Centre Groningen. [1]

Study Data

  • Condition: Ovarian Cancer and Pancreatic Cancer
  • Interventions:
    • Drugs used in this trial
      • 89Zr-MMOT0530A
      • DMOT4039A (DMOT-4039A / RG7600 / RG 7600)
  • Phase: I
  • Enrollment: 11
  • Start: March 2013
  • Completion: May 2014
  • Last verified: October 2014

Study Schematic 

NCT01832116 (CLINICAL TRIAL / DMOT4039A / RG7600)

Last Editorial review: July 29, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.